Signatera growth outruns legal overhang as approvals multiply
- Q2 2026 volume exceeded 1 million tests, driven by rapid oncology adoption.
- Signatera added a record 34,000 clinical oncology units sequentially in Q2.
- Signatera won FDA companion diagnostic approval and Japanese PMDA approval.
- Strong momentum sparked a $100 million revenue guidance raise for 2026.
- The main bear point remains about $349 million in patent verdicts that Natera is appealing.
Cancer testing is pulling the story
Natera continued its explosive growth in Q2 2026. Total tests processed exceeded 1.044 million. Oncology units processed reached 283,000, adding a record 34,000 sequentially. This performance led management to raise 2026 revenue guidance by another $100 million.
The bull case relies heavily on Signatera. This test looks for tiny traces of cancer DNA after treatment, which doctors call molecular residual disease. Signatera recently became the first MRD test to get FDA approval as a companion diagnostic. It also earned an NCCN Category 1 recommendation for bladder cancer, giving doctors more reason to order it.
The next layer of the bull case is global expansion. Signatera received PMDA approval in Japan, setting up a late 2026 launch. Management estimates this could effectively double the annual colorectal cancer volume market opportunity for the test.
The bear case is mostly confined to legal risk. Natera has about $349 million of adverse patent verdicts from Ravgen and Guardant Health that it is appealing. With operational growth blowing past expectations, the primary investment question is whether execution can consistently outweigh this specific legal and financial risk.
Labs, insurers, and test volume
Natera makes money by selling diagnostic tests. Most tests are run in its CLIA-certified labs, mainly in Austin, Texas and San Carlos, California. The company bills clinics, lab partners, patients, drug companies, and insurance payers.
The key payers are insurers. Natera says most revenue comes from insurers with in-network contracts. That gives the company more predictable payment, but the contracted price is usually below the list price. Growth depends on more doctors ordering tests, more payer coverage, and better average selling prices.
Natera also runs Constellation, a cloud model for partner labs. In that setup, another lab does the wet lab work and uses Natera's software algorithms. Natera gets lower revenue per test, but it also avoids much of the processing cost.
The model scales well when volumes rise faster than sales and lab costs. That is what bulls see in Signatera today. It can break if reimbursement weakens, if doctors stop ordering more tests, or if legal costs force a large cash payment.
Pregnancy roots, cancer engine
Signatera
Signatera is a personalized MRD test for cancer patients. It is the primary growth engine, recently adding FDA companion diagnostic and Japan PMDA approvals.
Panorama
Panorama is Natera's non-invasive prenatal test. The company recently launched an enhanced version specifically validated for low fetal fraction patients.
Horizon
Horizon is a carrier screening test used in women's health. Along with Panorama, it forms the mature base of the business.
Latitude
Latitude is a tissue-free MRD test for colorectal cancer. It could expand Natera's reach because it does not need a tumor tissue sample.
Fetal Focus
Fetal Focus is a single-gene NIPT product that was expanded to 21 genes. It adds a new layer to the women's health franchise.
Prospera
Prospera tests for transplant rejection in kidney, heart, and lung patients. It gives Natera a smaller but useful organ health footprint.
Constellation
Constellation licenses Natera's bioinformatics tools to other labs through the cloud. Revenue per test is lower, but so are processing costs.
Mostly U.S. direct selling
Natera reports one operating segment. Based on historic disclosures through early 2026, revenue leans heavily on the U.S. direct sales force (approximately 96%), with minimal international share pending the upcoming Japan launch.
What could go wrong
Patent verdict cash hit
High impact · Medium oddsNatera has adverse 2024 jury verdicts of $57 million from Ravgen and more than $292 million from Guardant Health. The total is about $349 million before any appeal outcome or other legal changes. This could materially reduce cash and hurt investor confidence.
Signatera volume slows
High impact · Medium oddsThe bull case depends on Signatera staying on a very fast adoption curve. Management reported a record 34,000 sequential clinical oncology unit adds in Q2 2026. If that pace drops significantly, the market may question the long-term growth story.
Coverage and pricing disappoint
High impact · Medium oddsNatera needs payer coverage and good average selling prices to turn test volume into profit. MolDx decisions on expanded Signatera submissions could add upside, but delays or lower payments would cap the benefit.
Japan launch execution
Medium impact · Medium oddsManagement expects a broad Japan launch for Signatera in late 2026 following recent PMDA approval. It says Japan could effectively double Signatera's annual colorectal cancer volume market opportunity. That upside depends on reimbursement, local sales execution, and doctor adoption.
Future LDT regulation returns
Medium impact · Low oddsA major near-term regulatory threat fell after a federal court vacated the FDA's LDT rule. However, Congress could still bring back a law such as the VALID Act. A new framework could add costs or slow test launches.
In one breath
What does Natera do?
Natera sells DNA-based diagnostic tests. Its biggest areas are women's health, cancer monitoring, and organ transplant health.
Why is Signatera important to Natera stock?
Signatera is the main growth driver. It helps detect tiny traces of cancer DNA after treatment. In Q2 2026, it added a record 34,000 clinical oncology units and secured key regulatory approvals.
What is the biggest risk for Natera?
The clearest single risk is the patent litigation overhang. Natera is appealing adverse verdicts tied to Ravgen and Guardant Health that total about $349 million.
